CCL2 and metabolic dysfunction-associated steatohepatitis: Suppressing the IL-33 signaling pathway can inhibit NASH progression by down-regulating CCL2 and α-SMA expression (46), while activating IL-19 signaling reduces HSC migration by down-regulating CCL2 expression, alleviating liver fibrosis (47).